top of page
All posts.
LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland
London , 28 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...
Apr 28, 2025
Professor John Campbell PhD FRSB shares insights into how treatment resistance in solid tumours can be overcome
We spoke to Professor John Campbell PhD FRSB, a member of our Scientific Advisory Board, to discuss a key question in oncology: How can treatment resistance in solid tumours be overcome?
Apr 24, 2025
Dr. Mark A. Exley shares what excites him most about joining LIfT as Chief Scientific Officer and the potential of LIfT’s technology
In this video, Dr. Mark A. Exley shares his background in biotech, what makes our neutrophil-based approach to cancer therapy so...
Apr 8, 2025
LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer
Mark brings 30 years of experience in R&D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in neutrophil immuno-therapies, today announces the appointment of Mark A. Exley, PhD as Chief Scientific Officer (CSO), effective 7 April. The appointment of a CSO with extensive clinical expertise comes at a pivotal time for LIfT, as the Company prepares for clinical tr
Apr 7, 2025
Dr Michael McCarthy discusses one of the biggest challenges in solid tumour treatment: treatment resistance
We spoke to Dr Michael McCarthy, Consultant Medical Oncologist at University Hospital Galway, regarding what treatment resistance in...
Apr 3, 2025
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics
Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’),...
Apr 3, 2025
Newsletter.
Stay up-to-date with our progress and latest news.
bottom of page